INTRODUCTION AND OBJECTIVES:
Renal cell carcinoma(RCC) is the third most common genitourinary cancer and accounts for about 2% of all cancers. However, it is difficult to differentiate precisely advanced and localized ccRCC without tumor biopsy and histopathological classification. In order to identify potential novel biomarkers of advanced clear cell renal carcinoma (ccRCC), we re-evaluated published long non-coding RNA (lncRNA) expression profiling data.
METHODS: The lncRNA expression profiles in ccRCC microarray dataset GSE47352 were analyzed including the expression of 2448 lncRNA transcripts in localized (stage I and II, n¼5) and advanced (stage III and IV, n¼4) ccRCC tissues. An independent cohort of 61 clinical samples including 21 advanced and 40 localized ccRCC patients was used to confirm the most statistically significant lncRNAs by real time PCR. Next, the relationships between the selected lncRNAs and ccRCC patients' clinicopathological features were investigated. The effects of LncRNAs on the invasion and proliferation of renal carcinoma cells were also investigated.
RESULTS: The PCR results in a cohort of 21 advanced ccRCC and 40 localized ccRCC tissues were used for confirmation of eight selected lncRNAs(ENSG00000241684, ENSG00000235501, ENSG00000231721, ENSG00000214145, NEAT1, ENSG00000244020, PSORS1C3, H19) which were statistically most significant in GSE47352. The PCR results showed that the expression of three LncRNA (ENSG00000241684, ENSG00000231721 and NEAT1) were significantly downregulated in advanced ccRCC. KaplaneMeier analysis revealed that reduced expression of LncRNA ENSG00000241684 and NEAT1 were significantly associated with poor overall survival. The univariate and multivariate Cox regression indicated LncRNA ENSG00000241684 had significant hazard ratios for predicting clinical outcome. LncRNA ENSG00000241684 expression was negatively correlated with pTNM stage. Overexpression of ENSG00000241684 significantly impaired cell proliferation and reduced the invasion ability in 786-O and ACHN cells.
CONCLUSIONS: lncRNAs are involved in renal carcinogenesis and decreased lncRNA ENSG00000241684 expression may be an independent adverse prognostic factor in advanced ccRCC patients.
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MP88-18 ERK5 IS A PROMISING THERAPEUTIC TARGET FOR CLEAR CELL RENAL CELL CARCINOMA
Hidenori Kanno*, Sei Naito, Osamu Ichiyanagi, Takahumi Narisawa, Hiromi Ito, Yamagata City, Japan; Akira Nagaoka, Yonezawa City, Japan; Suguru Ito, Shinta Suenaga, Hiroki Fukuhara, Yuta Kurota, Mayu Yagi, Atsushi Yamagishi, Toshihiko Sakurai, Hayato Nishida, Hisashi Kawazoe, Akihiko Abe, Takuya Yamanobe, Tomoyuki Kato, Norihiko Tsuchiya, Yamagata City, Japan INTRODUCTION AND OBJECTIVES: Clear-cell renal cell carcinoma (ccRCC) is characterized by a mutation in the von HippelLindau tumor suppressor gene (VHL). A recent study revealed that extracellular signal-regulated kinase 5 (ERK5) is degraded through the ubiquitin-proteasome system, in a process mediated by VHL and HIF. Several studies have demonstrated that microRNA 143 (miR143), which displays decreased expression in RCC cells, regulates ERK5 expression. Our objective was to examine the effect of ERK5 in ccRCC and to investigate the potential of ERK5 as a therapeutic target.
METHODS: ERK5 expression in tumor cells of RCC patients was investigated using immunohistochemistry (IHC). Effect of proteasome inhibition on ERK5 in RCC cell lines was examined by western blot analysis. The expression of miR143 in human RCC cell lines was analyzed by quantitative PCR. MTS assays, flow cytometry, and western blotting were used to assess the effect of XMD8-92-mediated ERK5 inhibition in human RCC cell lines. We introduced ERK5 siRNA into A498 cells to analyze the apoptotic effect. Furthermore, RCC xenografts in mice were treated with XMD8-92 to investigate the effect of ERK5 inhibition.
RESULTS: A total of 168 surgical specimens taken from patients with localized RCC were analyzed using IHCe82 (48.8 percent) were ERK5 positive and 20 (11.9 percent) were ERK5 strongly positive. Proteasome inhibition appeared to enhance ERK5 expression in wildtype cell lines, but not in VHL-mutant cell lines. An inverse correlation between ERK5 expression and miR143 quantification was observed in RCC specimens (n¼48, Fisher's exact test p¼0.0625). Furthermore, ERK5 inhibition resulted in the increase of the sub-G1 population as observed by flow cytometry, and cleaved RARP expression indicated an increase in apoptotic cells as seen by western blotting. ERK5 inhibition also reduced cell viability and ERK5 knockdown downregulated RARP and Bcl-2 expression. Also, XMD8-92 showed anti-tumor activity in tumor xenograft mice and it was observed Ki67 and CD34 expression downregulated following the treatment.
CONCLUSIONS: We observed that ERK5 expression in RCC was suppressed by miR143 expression. ERK5 degradation appears to involve the VHL pathway. The inhibition of ERK5 by XMD8-92 suggests induction of apoptosis. The anti-tumor effect of XMD8-92 shown in nude mouse xenograft tumor models may be due to the inhibition of angiogenesis. Our results suggest that ERK5 is a promising therapeutic target for the treatment of ccRCC. 
MP88-19 THE IMPORTANT ROLE OF GLYCINE N-METHYLTRANSFERASE IN THE PROLIFERATION OF RENAL AND UROTHELIAL CARCINOMA
Ario Takeuchi*, Masaki Shiota, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto, Fukuoka, Japan INTRODUCTION AND OBJECTIVES: Glycine N-methyltransferase (GNMT) plays a role in the metabolism of methionine as well as in gluconeogenesis. We have recently reported that the GNMT gene acts as an oncogene. However, little is known about the specific function of GNMT in carcinogenesis and tumor progression in urothelial carcinoma (UC) and renal cell carcinoma (RCC). To better our understanding of the function of GNMT in UC and RCC, we used small e1204 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 
